Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Methylphenidate works by slowing the removal of two naturally occurring brain chemicals — norepinephrine and dopamine — from the spaces between nerve cells. When these chemicals stay active a little longer, they help improve focus and attention. It's approved in Australia for attention deficit hyperactivity disorder.
The medication leaves the body relatively quickly, with a half-life of two to three hours, which means it's often taken more than once a day to maintain steady effects throughout waking hours.
Some serious effects require immediate medical attention. These include stroke-like symptoms — severe headache, weakness on one side of the body, trouble with coordination, vision, speech, language, or memory — and other blood vessel problems in the brain. If your family member experiences any of these, seek emergency care.
In children and adolescents, methylphenidate can temporarily slow growth. Over three years of continuous use, the average effect is about two centimetres less height and 2.7 kilograms less weight than would otherwise be expected. Doctors usually monitor growth during treatment.
The medication should not be used in people who have motor or verbal tics, or who have Tourette's syndrome, as it can make these conditions worse.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationAttention deficit hyperactivity disorder Clinical criteria: Patient must have demonstrated a response to immediate-release methylphenidate hydrochloride with no emergence of serious adverse events, AND Patient must require continuous coverage over 8 hours, AND The treatment must not exceed a maximum daily dose of 80 mg of PBS-subsidised treatment with this drug. Population criteria: Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive; OR Patient must have had a diagnosis of ADHD prior to turning 18 years of age if PBS-subsidised treatment is continuing beyond 18 years of age; OR Patient must have a retrospective diagnosis of ADHD if PBS-subsidised treatment is commencing after turning 18 years of age; OR Patient must have had a retrospective diagnosis of ADHD if PBS-subsidised treatment is continuing in a patient who commenced PBS-subsidised treatment after turning 18 years of age. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner who is continuing treatment with this medicine (of any strength) that was initiated by a medical practitioner as a PBS benefit. A retrospective diagnosis of ADHD for the purposes of administering this restriction is: (i) the presence of pre-existing childhood symptoms of ADHD (onset during the developmental period, typically early to mid-childhood); and (ii) documentation in the patient's medical records that an in-depth clinical interview with, or, obtainment of evidence from, either a: (a) parent, (b) teacher, (c) sibling, (d) third party, has occurred and which supports point (i) above.
“Methylphenidate is a central nervous system (CNS) stimulant. Its mode of action in humans is not completely understood but methylphenidate presumably exerts its stimulant effect by an inhibition of dopamine and norepinephrine reuptake into presynaptic neurons and thereby increasing these neurotransmitters in the extraneuronal space.”
“Methylphenidate is eliminated from the plasma with a mean half-life of 2 to 3 hours, and the calculated mean systemic clearance is 4 to 10 L/h/kg after an oral dose.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Methylphenidate is a centrally acting sympathomimetic classified as a norepinephrine–dopamine reuptake inhibitor. It is a benzylpiperidine and phenethylamine derivative that shares part of its basic structure with catecholamines. The drug is scheduled as S8 and carries TGA-approved indication for attention deficit hyperactivity disorder.
The plasma half-life is 2–3 hours. Serious adverse effects include cerebrovascular disorders, cerebral ischaemia, and manifestations such as severe headache, unilateral weakness or paralysis, and impairment of coordination, vision, speech, language, or memory. Long-term use in paediatric populations is associated with temporary slowing in growth rate, averaging about 2 cm less growth in height and 2.7 kg less growth in weight over three years. Motor and verbal tics, as well as worsening of Tourette's syndrome, are contraindications to use.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.